Tag Archives: Cegedim
By Guest Blogger | Published: September 11, 2014
The role of medical affairs is taking on greater importance, as relationships between life sciences companies and external stakeholders become more complicated. Medical affairs is required to communicate more often with medical practitioners, scientific researchers, patients, patient advocates, and government authorities, and to provide these groups with more complex and more comprehensive information. Unfortunately, many […]
By Pharm Exec | Published: June 5, 2014
Industry investment in pharma sales force and marketing channels remained “flat” in 2013 at just under €85 billion constant US dollars, according to newly released data from Cegedim Strategic Data (CSD).
By Julian Upton | Published: February 15, 2012
As the perceived urgency for transparency and compliance in global pharma grows ever stronger, the ‘Sunshine provisions’ of the US’s Patient Protection and Affordable Care Act (ACA) seem increasingly aptly named. The spotlight that has been exposing and illuminating – and sometimes burning – issues around the financial interests of physicians and academic medical centers […]
By Ben Comer | Published: October 17, 2011
Last year, only two percent of the respondents surveyed by Cegedim cited regulatory and compliance issues as a driver of new technology adoption, and six percent said regulatory and compliance was a primary driver of pharmaceutical business model or process change. A lot can happen in a year.